ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2516

Mortality Trends in Primary Systemic Vasculitis in the United States (1999–2023)

Rameez Qasim1, Sabah Mohib2, Muhammad Ali3 and Khadija Mohib4, 1Allama Iqbal Medical College Lahore, Lahore, Pakistan, 2N/A, Reseda, CA, 3Dow International Medical College, Karachi, Sindh, Pakistan, 4Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV

Meeting: ACR Convergence 2025

Keywords: ANCA, ANCA associated vasculitis, Mortality, Vasculitis, Vasculitis, Cutaneous

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2504–2523) Vasculitis – ANCA-Associated Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Primary systemic vasculitides comprise a group of immunological disorders that inflame blood vessel walls and are categorized by the size of the blood vessels involved (small, medium, and large vessel vasculitis). This group of disorders has an elevated mortality rate among rheumatologic diseases, as prior studies have suggested. While earlier analyses have studied mortality trends related to this group of disorders, newer, more updated research is limited, especially concerning trends beyond 2019.

Methods: Datasets from the CDC WONDER Multiple Cause-of-Death public use records from 1999 to 2023 were used to analyze deaths in adults ≥25 years old, assigning ICD-10 codes (M30 and M31 series) to primary systemic vasculitis by year and place of death, as well as by demographic (sex, age group, race) and regional (state, census region, rural-urban) stratifications. Age-adjusted mortality rates (AAMR) were calculated per 1,000,000 with 95% confidence intervals by standardizing crude mortality rates (CMR). Annual percent change (APC) and average annual percent change (AAPC) were evaluated using Joinpoint regression software.

Results: A total of 39,093 deaths occurred from 1999 to 2023, mostly in medical facilities (61.8%). The AAMR declined from 11.2 in 1999 to 4.9 in 2023 (AAPC: -3.3; 95% CI: -3.6 to -2.9). Women had a higher average AAMR compared to men, along with a higher rate of decrease (AAPC women: -3.4; 95% CI: -3.8 to -3.0; men: -2.9; 95% CI: -3.3 to -2.4). Adults aged ≥65 years had the highest average AAMR, along with the highest rate of decrease among the age groups (AAPC ≥65 years: -3.4; 95% CI: -3.7 to -3.0; 45–65 years: -2.9; 95% CI: -3.5 to -2.4; 25–44 years: -2.2; 95% CI: -3.2 to -1.3).Racially, non-Hispanic (NH) White populations had the highest average AAMR, along with the highest rate of decrease (AAPC NH White: -2.7; 95% CI: -3.3 to -2.2; NH Asian/Pacific Islander: -2.9; 95% CI: -3.8 to -2.0; Hispanic/Latino: -3.0; 95% CI: -3.7 to -2.1; NH Black/African American: -3.3; 95% CI: -4.0 to -2.6).Regionally, the Midwest had the highest average AAMR, though the South had the highest rate of decrease (AAPC South: -3.4; 95% CI: -3.8 to -3.0; West: -2.8; 95% CI: -3.6 to -2.1; Midwest: -3.1; 95% CI: -3.6 to -2.6; Northeast: -3.2; 95% CI: -3.7 to -2.7).From 1999 to 2020, state-wise AAMRs ranged from 5.1 in Hawaii to 12.6 in Vermont. From 2021 to 2023, AAMRs ranged from 3.7 in Louisiana to 11.8 in Minnesota. From 1999 to 2020, rural areas had a higher average AAMR, though urban areas had a higher rate of decrease (AAPC urban: -3.8; 95% CI: -4.1 to -3.4; rural: -2.5; 95% CI: -3.0 to -2.0).

Conclusion: Though primary systemic vasculitis-related mortality rates in adults declined from 1999 to 2023, disparities across demographic and regional groups remain, highlighting the need for targeted prevention and support systems to improve outcomes in at-risk communities.

Supporting image 1Trends in Vasculitis-Related Mortality by Race, United States (1999–2023)

Supporting image 2Primary Systemic Vasculitis Mortality by Sex (1999–2023)

Supporting image 3Primary Systemic Vasculitis Mortality by Census Region (1999–2023)


Disclosures: R. Qasim: None; S. Mohib: None; M. Ali: None; K. Mohib: None.

To cite this abstract in AMA style:

Qasim R, Mohib S, Ali M, Mohib K. Mortality Trends in Primary Systemic Vasculitis in the United States (1999–2023) [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/mortality-trends-in-primary-systemic-vasculitis-in-the-united-states-1999-2023/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-trends-in-primary-systemic-vasculitis-in-the-united-states-1999-2023/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology